Low-pro­file start­up stakes its claim to Sanofi's siR­NA plat­form in wake of set­backs

A biotech in Chi­na re­ports to­day that it will be scoop­ing up a string of pre­clin­i­cal siR­NA pro­grams from Sanofi as the multi­na­tion­al play­er lat­er­als a dor­mant de­vel­op­ment plat­form to the Lil­ly-backed group in Shang­hai.

De­tails are sparse, but Rona Ther­a­peu­tics — which scored a $33 mil­lion launch round in April from Lil­ly Asia Ven­tures, CMB In­ter­na­tion­al, Pla­tanus, Fontus Cap­i­tal and Lant­i­ng Cap­i­tal — says it gained world­wide ex­clu­sive rights to Sanofi’s siR­NA plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER